Aderbasib

Aderbasib

Clinical data
Routes of administration	Oral
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name methyl (6S,7S)-7-(hydroxycarbamoyl)-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate
CAS Number	791828-58-5
PubChem (CID)	16070111
ChemSpider	17229620
ChEMBL	CHEMBL1376060
Chemical and physical data
Formula	C21H28N4O5
Molar mass	416.47 g·mol^−1
3D model (Jmol)	Interactive image
SMILES COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO
InChI InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1 Key:DJXMSZSZEIKLQZ-IRXDYDNUSA-N

Aderbasib (INN/USAN, codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.^[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.^[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.^[3][4]

References

1. "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
2. "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
3. Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
4. "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.

External links

• NCI Thesaurus